| Keywords: |
vasculotropin; mortality; unspecified side effect; outcome assessment; low drug dose; interleukin 10; interleukin 4; inflammation; inflammation mediators; editorial; drug effect; angiogenesis; prediction; tumor necrosis factor alpha; interleukin 6; therapy effect; methylprednisolone; neovascularization, physiologic; plasminogen activator inhibitor 1; coagulation; artificial ventilation; respiratory failure; critical illness; adult respiratory distress syndrome; blood coagulation; acute lung injury; acute respiratory distress syndrome; corticosteroid therapy; fibrinolysis; tidal volume; protein c; respiratory distress syndrome, adult; procalcitonin; drotrecogin; proadrenomedullin
|
